1. Search Result
Search Result
Results for "

zymogen activation

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144813

    Cathepsin Inflammation/Immunology Cancer
    Gü2602 is a potent, reversible cathepsin K (CatK) inhibitor with a Ki of 0.013 nM for mature CatK (mCatK). Gü2602 suppresses the autocatalytic activation of the cathepsin K zymogen .
    Gü2602
  • HY-P99415

    MAA868

    Factor Xa Cardiovascular Disease
    Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
    Abelacimab
  • HY-108904

    Urokinase-type plasminogen activator; Uronase; Win 22005; Win-Kinase

    Ser/Thr Protease Cardiovascular Disease Cancer
    Urokinase (peptidolytic) (EC 3.4.21.73) is a serine protease, an inactive form (zymogen) of the serine protease plasminogen. Activation of plasmin triggers a proteolytic cascade reaction, which in turn participates in thrombolysis or extracellular matrix degradation, implicated in vascular disease and cancer-related research .
    Urokinase, Human urine
  • HY-E70391

    Others Others
    C1r Enzyme is the activated form of the C1r zymogen and serves as an activator of Cls .
    C1r Enzyme
  • HY-144812

    Cathepsin Inflammation/Immunology Cancer
    Gü1303 is a potent, reversible, slow-binding cathepsin K (CatK) inhibitor with a Ki of 0.91 nM for mature CatK (mCatK). Gü1303 suppresses the autocatalytic activation of the cathepsin K zymogen .
    Gü1303